Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Puma

- PMLiVE

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

The European Medicines Agency is also reviewing an application for the drug

- PMLiVE

EMA begins rolling review process for Sputnik V COVID-19 vaccine

Late-stage trial results found vaccine gives 91.6% protection against COVID-19

- PMLiVE

AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset

Company can acquire asset following the completion of IND enabling studies

- PMLiVE

UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people

Data suggests vaccine is 80% effective at preventing hospitalisations in over-80s

- PMLiVE

FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine

Vaccine can be transported/stored at standard pharmaceutical freezer temperatures

- PMLiVE

UK approval for Seagen’s oral HER2 inhibitor Tukysa

MHRA has authorised drug for HER2-positive advanced breast cancer

- PMLiVE

Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures

New data shows vaccine can be stored at temperatures of -25°C to -15°C

- PMLiVE

Researchers suggest delaying second dose of Pfizer/BioNTech jab to protect more people

Canada-based researchers Skowronski and De Serres say first dose is ‘highly protective’

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

EU flag

Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU

The EU now currently has access to 2.6 billion COVID-19 vaccine doses from a range of companies

- PMLiVE

South African variant reduces antibody levels produced by Pifzer/BioNTech’s COVID-19 vaccine

Researchers noted it is 'unclear' what effect this reduction has on the vaccine's protection against the variant

- PMLiVE

Three strategies for managing loss of exclusivity successfully

Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links